XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2023
May 31, 2022
Aug. 31, 2017
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Jun. 26, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Gain (loss) on extinguishment of debt           $ 0 $ (313)    
Contract liabilities, net of current portion       $ 18,669   18,669     $ 18,669
Revenue       0 $ 0 1,000 0    
G42 Investments                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Shares sold (in shares)   259,657              
Sale of stock, price per share (in usd per share)   $ 96.40              
Sale of stock, consideration received on transaction, gross   $ 25,000              
Sale of stock, consideration received on transaction   12,500              
Accounts and financing receivable, after allowance for credit loss   12,500              
Proceeds from collection of notes receivable $ 12,000                
Discount rate 3.75%                
Gain (loss) on extinguishment of debt $ (300)                
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Sale of stock, consideration received on transaction, gross   25,000              
Accounts and financing receivable, after allowance for credit loss   12,500              
Proceeds from collection of notes receivable $ 12,000                
Discount rate 3.75%                
Gain (loss) on extinguishment of debt $ (300)                
Collaborative arrangement, contingent consideration   30,000              
Collaborate arrangement, contingent consideration transferred, cash   $ 30,000              
Contract liabilities, net of current portion       18,700   18,700      
Discount on note receivable           600      
Collaboration revenue recognized       0   0      
Revenue       0 $ 0 0      
Receivables, fair value disclosure       $ 11,900   11,900      
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Royalties receivable, period   10 years              
Collaborative Arrangements | Newsoara Biopharma Co Ltd                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Contract with customer, liability, revenue recognized             $ 0    
Collaborative Arrangements | Newsoara Biopharma Co Ltd                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
License fee received               $ 20,000  
License fee received, term               1 year  
Potential development and regulatory milestone payments               $ 76,500  
License fee price increase               $ 20,000  
Collaborative Arrangements | Newsoara Biopharma Co Ltd | License And Technology Transfer Services                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized from change in estimated transaction prices           $ 1,000      
Collaborative Arrangements | JDRF                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Maximum funding percentage of research and development milestones     50.00%